A new clinical trial with a rather innovative use of cyclodextrins is about to start shortly, although the recruitment has not started yet. The aim is inguinal hernia repair with CycloMesh™ soaked in ropivacaine hydrochloride.
CycloMesh is a polyester visceral implant functionalized by drug delivery systems directly on its surface, targeting a unique intervention, a slow anesthetic release and an in situ activity. Based on the fact that cyclodextrins are capable of forming inclusion complexes with amino-amide anaesthetic agents, ropivacaine and cyclodextrins were combined on a commercial visceral mesh. This enables CycloMesh to release ropivacaine for a sustained period in order to improve patient’s comfort after inguinal hernia surgery.
The underlying hypothesis of this work is that clinical gain is achieved by adding a drug delivery system to visceral mesh for the local and prolonged delivery of ropivacaine. This should results in an improvement in quality of life, a reduction in pain and a faster returning to work following treatment of inguinal hernia by lichtenstein technique.